

REMARKS/ARGUMENTS

Applicants thank Examiner Stockton for indicating that Claim 9, if re-written toward elected subject matter, would appear to be allowable over the art of record.

Claims 21-22 are new.

Claims 1, 5-6, 10-11 and 14-18 are canceled.

Support for each new and amended claim is found at the originally filed claims and throughout the specification.

Upon entry of the amendment, Claims 2-4, 7-9, 12-13, and 19-22 will be active.

No new matter is believed to have been added.

The objections to Claims 12-14 and 18 are obviated by cancellation of these claims.

Applicants respectfully traverse the 35 U.S.C. 112, first paragraph, rejection of Claims 13 and 18-20. The rejection of Claims 18 is obviated by cancellation of Claim 18. Claim 13 has been amended to recite treating pain, inflammatory diseases, thrombosis, or a combination thereof. Applicants submit that the specification, and literature extant at the time of filing of the patent, support treating of these diseases by inhibiting COX. Further, the treating and disease limitations are incorporated into Claims 19 and 20. Accordingly, Applicants respectfully request withdrawal of this rejection.

Applicants respectfully traverse the 35 U.S.C. 112, second paragraph, rejection of Claims 1-8, 12-15, and 18-20.

The rejection of Claims 1, 5-6, 14-15, and 18 is obviated by cancellation of these claims.

Claim 2 has been amended to recite diphenyl oxazole compounds where the phrase "described later on..." has been replaced with the phrase "is substituted with at least one substituent selected from the group consisting of..." Claims 13 and 20 have been amended

to remove the expression "and/or" and, in its place, recite a method of treating. Accordingly, Applicants request withdrawal of the 35, U.S.C. 112, second paragraph, rejection.

Applicants respectfully traverse the 35 U.S.C. 102(b) rejection of Claims 1-8, 12-15, and 18-20 as being anticipated by various references.

The rejection of Claims 1, 5-6, 14-15, and 18 are obviated by cancellation of these claims. Applicants have amended Claim 2 to describe a chemotype having a diphenyl oxazole core wherein the phenyl group on the 5-position of the oxazole ring has a characteristic substituent,  $R^5-R^4-(X)_n-$ , at the phenyl ring 4-position. Applicants submit that this chemotype is not described in, or suggested by, the cited references, and that the rejection should therefore be withdrawn for Claim 2, and the claims depending therefrom.

Applicants respectfully traverse the 35 U.S.C. 103(a) rejection of Claims 1-6, 8, 12-14 and 18-20.

The rejection of Claims 1, 5-6, 14, and 18 is obviated by cancellation of these Claims.

Applicants have amended Claim 2 to describe a chemotype having a diphenyl oxazole core wherein the phenyl group on the 5-position of the oxazole ring has a characteristic substituent,  $R^5-R^4-(X)_n-$ , at the phenyl ring 4-position. Applicants submit that this chemotype is not suggested by the cited references, and that the rejection should therefore be withdrawn for Claim 2, and the claims depending therefrom.

Claim 9 has been amended to place the claim in condition for allowance.

Applicants respectfully request rejoinder of the method claims depending from or otherwise including all of the limitations of any allowed composition claim.

Applicants submit the present application has now been placed in condition for allowance. Early notification thereof is earnestly solicited.

Application No. 10/758,253  
Reply to Office Action of February 21, 2006


Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.  
Norman F. Oblon

Customer Number

**22850**

Tel: (703) 413-3000  
Fax: (703) 413 -2220  
(OSMMN 06/04)

  
\_\_\_\_\_  
Charles J. Andres Jr., Ph.D.  
Attorney of Record  
Registration No. 57,537